PT - JOURNAL ARTICLE AU - Chen, Siyu AU - Flegg, Jennifer A AU - White, Lisa J AU - Aguas, Ricardo TI - Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys AID - 10.1101/2021.01.08.21249432 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.08.21249432 4099 - http://medrxiv.org/content/early/2021/03/14/2021.01.08.21249432.short 4100 - http://medrxiv.org/content/early/2021/03/14/2021.01.08.21249432.full AB - Accurate knowledge of accurate levels of prior population exposure has critical ramifications for preparedness plans of subsequent SARS-CoV-2 epidemic waves and vaccine prioritization strategies. Serological studies can be used to estimate levels of past exposure and thus position populations in their epidemic timeline. To circumvent biases introduced by decaying antibody titers over time, population exposure estimation methods should account for seroreversion, to reflect that changes in seroprevalence measures over time are the net effect of increases due to recent transmission and decreases due to antibody waning. Here, we present a new method that combines multiple datasets (serology, mortality, and virus positivity ratios) to estimate seroreversion time and infection fatality ratios and simultaneously infer population exposure levels. The results indicate that the average time to seroreversion is six months, and that true exposure may be more than double the current seroprevalence levels reported for several regions of England.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJF acknowledges receives funding from the Australian Research Council (DP200100747). LJW is funded by the Li Ka Shing Foundation, and the University of Oxford's COVID-19 Research Response Fund (BRD00230). RA is funded by the Bill and Melinda Gates Foundation (OPP1193472).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, code, and materials used in the analyses can be accessed at:https://github.com/SiyuChenOxf/COVID19SeroModel/tree/master